Lyvgen Biopharma Presents Clinical Trial Data of CD137/4-1BB Agonistic Antibody LVGN6051 at the 2021 ASCO Annual Meeting

Shanghai, Suzhou, 4 June, 2021--Lvgen Biopharma, a biotech company focused on developing innovative immuno-oncology therapeutics, announces that it will present a Trials in Progress poster presentation at the American Society of Clinical Oncology Annual Meeting (ASCO), to be held in a virtual format from June 4 to 8, 2021.

The Trials in Progress poster presentation summarizes the safety profile, antitumor activity observed in a phase I clinical trial (NCT04130542) in collaboration with Merck & Co., Inc., Kenilworth, New Jersey, U.S.A., known as MSD outside of the U.S. and Canada. The trial is evaluating LVGN6051, a second generation 4-1BB (CD137) agonist antibody based on Lyvgen proprietary xLinkAb platform, as monotherapy or in combination with KEYTRUDA® (pembrolizumab), MSD’s anti-PD-1 therapy, in adult patients with advanced malignancies. No MTD was reached at 7 mg/kg monotherapy and 4 mg/kg q3w monotherapy was determined as RP2D. Preliminary antitumor activity in late stage cancer patients was observed. Combination with pembrolizumab induced rapid antitumor responses in advanced cancer patients with immune-cold tumor or relapsed from prior immunotherapies.

June 4, 2021

Lyvgen Biopharma Completes Series C Funding Led by IDG Capital

February 23, 2021 - Lyvgen Biopharma, a biotech company focused on developing innovative immuno-oncology therapeutics, announces that it has completed Series C founding. This round of financing was led by IDG Capital and included Shanghai FTZ Fund, Suzhou Longmen Venture Capital, CHENGWEI Capital and others, with China Renaissance Group as the exclusive financial adviser.

February 23, 2021

Lyvgen Announces First in Human Dosing of LVGN7409 CD40 Agonist Monoclonal Antibody in a Phase 1 Clinical Trial for the Treatment of Advanced or Metastatic Malignancy in the US

January 26, 2021 - Lyvgen, a clinical-stage biotechnology company, today announced first-in-human (FIH) dosing of its xLinkAb product LVGN7409 (CD40 agonist), a bi-functional monoclonal antibody optimally activating CD40 upon FcγRIIB-mediated cross-linking.

January 26, 2021

Lyvgen Appoints Xiaofeng Liu, Ph.D. as Senior Vice President of Manufacturing & Drug Development

Suzhou, China, October 19, 2020 – Lyvgen Biopharma, a biopharmaceutical company focused on developing innovative immuno-oncology therapeutics, is pleased to announce today the appointment of Xiaofeng Liu, Ph.D. as Senior Vice President of Manufacturing & Drug Development. This appointment forms part of Lyngen’s strategic drive to strengthen CMC capabilities including GMP manufacturing.

October 19, 2020

Lyvgen Biopharma (Suzhou) officially opened in BioBAY, Suzhou, China.

Lyvgen Biopharma (Suzhou) officially opened in BioBAY on June 10, 2020. Founded by Dr. Jieyi Wang in 2016, Lyvgen focuses on the development of novel immune-oncology (IO) agonist antibodies. At present, the company has built an CMC center of 2,000 square meters of therapeutic antibodies in BioBAY, Suzhou, China. The company headquarters, R&D center and GMP production site are also under active preparation. Follow us on Linkedlin.

June 10, 2020

Lyvgen Announces Clinical Trial Collaboration With MSD

Phase 1 clinical trials evaluating LVGN6051 second generation 4-1BB (CD137) agonist antibody and KEYTRUDA® (pembrolizumab) for the treatment of multiple types of cancer.

June 09, 2020

Copyright © 2020 LYVGEN BIOPHARMA. All RightsReserved.